生命科学资讯
生物技术与制药领域的最新动态
制药业或即将突破血脑屏障。
Pharma could be on the cusp of finally breaking the blood-brain barrier
人工智能正削减各行业岗位，制药业会步后尘吗？
AI is slashing jobs across industries. Will pharma be next?
更多药企转向癌症联合疗法，患者能否因此延长寿命？
More drugmakers are turning to cancer combos. Will it help patients live longer?
赛诺菲为求更“严谨”，以默克前CEO接替赫德森。
Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief
Ovid在新CEO领导下再次在神经科学领域大展拳脚。
Ovid takes another big swing in neuroscience under a new CEO
礼来公司24亿美元押注现货细胞疗法，彰显大型药企战略转型趋势。
Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
专为太空设计的蛋白质模型或将拓展制药业对“可成药性”的定义范畴。
A protein model designed for space could expand pharma’s definition of ‘druggability’
FDA新指南对临床试验意义重大
New FDA guidance that’s a ‘huge deal’ for clinical trials
在艰难市场中，生物科技公司可能成为自身最大的敌人。
In a tough market, biotechs can be their own worst enemy
新诊断方法为阿尔茨海默病、帕金森病及其他疾病定义药物靶点
New diagnostics define drug targets for Alzheimer’s, Parkinson’s and beyond
拜耳为制药业务复苏铺平道路
Bayer sets the stage for a pharma comeback
最有前途的GLP-1类药物
The most valuable up-and-coming GLP-1s
大型药企CEO瞄准未来数年实现大规模增长。
Big Pharma CEOs set sights on massive growth in years to come
特朗普医保计划为何在起步前就步履蹒跚
Why TrumpRx is stumbling before it gets off the ground
投资者青睐更安全、市场成熟度高的生物科技项目，早期融资缺口进一步扩大。
Investors crave safer, market-ready biotech bets, widening the early-stage funding gap
Mirum加倍押注多元化罕见病战略。
Mirum doubles down on diversified rare disease strategy
尽管AI已进入高风险患者护理领域，监管却滞后不前。
AI regulation lags despite entering higher-risk patient care
2026年制药业展望：前路是否更加顺畅？
Pharma’s outlook in 2026: Smoother sailing ahead?
大型制药企业如何应对3000亿美元专利悬崖
How Big Pharma is navigating a $300 billion patent cliff